A New Combination Therapy Regimen Shows Promising Results For Prostate Cancer
TALAPRO-2 demonstrated that using talazoparib in combination with enzalutamide may reduce the risk of disease progression or death by 37%.
Source: onclive.com
Stay updated with breaking news from Cancer Learning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TALAPRO-2 demonstrated that using talazoparib in combination with enzalutamide may reduce the risk of disease progression or death by 37%.
Cancer Australia has released a range of new tools and learning modules to support health professionals in primary care in the effective and accurate